Finance

Lists
Why is ENGN up 2,56%?
Dive Deeper
ENGN:NASDAQ
enGene Therapeutics Inc
USD 2,00
+2,56%
(+0,050) 1D
USD 1,89
-5,50% (-0,11)
Pre-market
Closed: 30 Sep., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ENGN...
Open
USD 1,96
High
USD 2,02
Low
USD 1,93
Mkt. cap
134,03 m
Avg. vol.
712,35 k
Volume
19,12 k
52-wk high
USD 12,25
52-wk low
USD 1,40
EPS
-USD 2,08
Beta
-0,28
Shares outstanding
67,02 m
No. of employees
82
Open
USD 1,96
High
USD 2,02
Low
USD 1,93
Mkt. cap
134,03 m
Avg. vol.
712,35 k
Volume
19,12 k
52-wk high
USD 12,25
52-wk low
USD 1,40
EPS
-USD 2,08
Beta
-0,28
Shares outstanding
67,02 m
No. of employees
82
News stories
From web sources and news partners
About enGene Therapeutics Inc
CEO-
Employees82
Founded-
Headquarters-
Sector-
Websiteengene.com
Analyst ratings
Based on 5 analysts giving stock ratings to ENGN in the past 3 months
Hold
Buy
1
Hold
3
Sell
1
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ENGN in the last 3 months.
Highest
Current USD 2,00
USD 4,00 (+100,00%)
Average
USD 2,50 (+25,00%)
Lowest
USD 2,00 (0,00%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Dai
UBS
Hold
Reiterated
USD 2,00
0%
09/16/2026
Mani Foroohar
Leerink Partners
Hold
Reiterated
USD 2,00
0%
09/09/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
USD 4,00
+100%
09/09/2026
Judah Frommer
Morgan Stanley
Sell
Maintained
-
-
08/12/2026
Yanan Zhu
Wells Fargo
Hold
Reiterated
USD 2,00
0%
08/12/2026
Michael Schmidt
Guggenheim
Hold
Maintained
-
-
06/16/2026
Leland Gershell
Oppenheimer
Hold
Maintained
-
-
05/08/2026
Sean McCutcheon
Raymond James
Buy
Maintained
USD 4,00
+100%
05/08/2026
Allison Bratzel
Piper Sandler
Hold
Downgraded
USD 4,00
+100%
05/08/2026
Silvan Tuerkcan
Citizens JMP
Hold
Downgraded
-
-
05/08/2026
Unknown Analyst
WBB Securities
Buy
Initiated
USD 21,50
+975%
04/13/2026
Xin Yang NG‏
USmart Securities
Buy
Initiated
USD 21,50
+975%
04/13/2026
Xin Yang NG‏
USmart Securities
Buy
Initiated
USD 21,50
+975%
04/13/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
-
-
03/26/2026
Maury Raycroft
Jefferies
Buy
Maintained
USD 28,00
+1 300%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Okt. 2025
Jan. 2026
Apr. 2026
Jul. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
31,72 m
22,26 m
22,20 m
20,09 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,76 m
8,93 m
9,77 m
13,92 m
Operating expense
39,48 m
31,18 m
31,97 m
34,01 m
Total operating expenses
39,48 m
31,18 m
31,97 m
34,01 m
Operating income
-39,48 m
-31,18 m
-31,97 m
-34,01 m
Other non operating income
448,00 k
-
-
-
EBT including unusual items
-38,38 m
-29,75 m
-30,23 m
-32,50 m
EBT excluding unusual items
-38,38 m
-29,26 m
-30,23 m
-32,50 m
Income tax expense
-497,00 k
-
-
-
Effective tax rate
1,29%
-
-
-
Other operating expenses
-
-
-
-
Net income
-37,88 m
-29,75 m
-30,23 m
-32,50 m
Net profit margin
-
-
-
-
Earnings per share
-0,73
-0,44
-0,43
-0,47
Interest and investment income
1,98 m
2,74 m
2,66 m
2,40 m
Interest expense
-750,00 k
-732,00 k
-745,00 k
-843,00 k
Net interest expenses
1,22 m
2,01 m
1,92 m
1,56 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-39,31 m
-31,00 m
-31,79 m
-33,84 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme